frenzy, page-45

re: sirtex goal: $5 then $8 -$9 The Bioshares estimate is very conservative as it doesn't include Australian reimbursement from the 24 Australian centers which the company received already, nor European payors which are coming in the future as indicated at the meeting,US centre growth,nor any new indications for the Sir Spheres which is the potential biggest market and which results of upcoming trials will begin to show is clearly the case . The sp has large upside as the company is only treating 0.5 % of the eligible population currently very profitably. My opinion only after being in the industry a while. Do your own work.